Optimizing Oncology Trials with a ctDNA Test Custom-Built for MRD and Molecular Monitoring

Natera_Oncology_listing_250x190

Join this webinar to discover the advantages of using Signatera™ (RUO), a novel assay custom-designed for each patient that detects circulating tumor DNA (ctDNA) with high sensitivity and specificity to monitor molecular residual disease, early recurrence, and treatment response across solid tumors. Register Now!